Gw Pharma ADR (GWPH)
$137.03 0.00 (0.00%)
19:18 EDT GWPH Stock Quote Delayed 15 Minutes
Previous Close $137.03
Market Cap 3.86B
PE Ratio -
Volume (Avg. Vol.)
Day's Range 137.03 - 137.03
52-Week Range 90.14 - 196.00
Dividend & Yield N/A (N/A)
GWPH Stock Predictions, Articles, and Gw Pharma ADR News
- From InvestorPlace
- From the Web
There was good news for marijuana stocks today after GW Phamaceuticals (GWPH) announced recent results from a late-stage study.
The future of marijuana stocks is a viable concept, as legalization will increase the use of pot and millions more potential users will try it.
Marijuana stocks like Cronos, Cannabis Sativa and Canopy Growth are just a handful of the names worth a closer look here.
New Age Beverages stock got a bit of a boost on Friday as the company prepares to launch its upcoming CBD drinks in select states.
GW Pharmaceuticals stock was on the rise Thursday following news of its epilepsy drug Epidiolex getting a Class V rating.
GWPH stock was up over 2.7% as the DEA is set to reclassify Epidiolex (cannabidiol) to be allowed for medicinal use in the coming months.
When looking at marijuana stocks, it's important to remember that how you play a big sector rally matters most. Here's what you need to know about stocks based in the cannabis space.
According to Wall Street, these 7 stellar strong buy stock picks all boast over 30% upside potential from their current prices.
The cannabis market has $100 billion-plus potential, but cannabis stocks won't start to realize that potential until a few years down the road.
GW Pharmaceuticals (GWPH) stock remained unchanged after hours on Tuesday despite the company posted a loss that was wider than it was in the year-ago quarter.
For those unfamiliar with Dravet syndrome, it’s a rare genetic condition that hits newborns and results in seizures caused by fever and involuntary muscle spasms. Young children who develop this condition tend to experience difficulty speaking, reduced motor skills, and hyperactivity.
Although GW Pharmaceuticals scored a major regulatory win, GWPH stock fell due to the specter of political headwinds.
After taking a pause in its uptrend, marijuana stocks could get a lift again as Molson Coors shops for companies in this sector. Though the sector has yet to prove it is profitable, a buyout will lift nearly all marijuana stocks.
GW Pharmaceuticals (GWPH) got some positive marijuana news from the U.S. Food and Drug Administration on Monday concerning its drug Epidiolex.
While the GW Pharma CBD drug Epidiolex is about to be approved by the FDA, the real change should be the federal government’s legalization of cannabis.
GW Pharmaceuticals (GWPH) shares were slipping after the bell as the company beat quarterly revenue estimates but missed earnings expectations.
Marijuana ETFs may still be few and far between, but these three are more than enough to get regular investors safely into the game.
High-risk stocks are in plentiful supply, but TIVO, JCP, APRN, GWPH, F, CBWTF and SHOP are seven choices that have the potential to deliver impressive returns.
PM stock has a proven track record of strong management. The demise of its industry has been erroneously called too many times. This too shall pass.
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!